FINWIRES · TerminalLIVE
FINWIRES

Canadian Dollar Prospects Should Improve, Follow An Appreciating Trend To Year End, says BMO

-- Higher oil prices haven't provided lasting support for the Canadian dollar (CAD or loonie), amid escalating geopolitical and global economic risks, along with fading Federal Reserve rate cut prospects that have boosted the US dollar (USD), says Bank of Montreal (BMO).

Even markets continuing to price in Bank of Canada rate hikes have failed to provide lasting support, adds the bank, noting that from the close on Feb. 27, the Canadian dollar has weakened a net 1.5% to around $1.385 (US$0.722).

But, BMO says, as the U.S. dollar's boost from the Iranian conflict ebbs and Fed rate cuts resume, and with the BoC on a long pause, Canadian dollar prospects should improve.

The bank says it looks for the CAD to follow an appreciating trend to $1.33 (US$0.752) by the end of 2026 as the Canadian economy rebounds after being hit disproportionately by the United States trade policy.

Still, BMO adds, trade policy is a key risk for the Canadian dollar and the broader economy, with the review of the USMCA scheduled by July 1. BMO's working assumption is that the agreement won't be renewed and neither will any party give its six months' notice to exit.

Instead, BMO expects a sequence of annual negotiation intervals to commence, which could last for at least the next two or three years.

Meantime, while new Section 122 10% tariffs applied to USMCA noncompliant goods only, new national security or sectoral tariffs loom (Section 232) and Canada has been mentioned in the Section 301 investigations into unfair trade practices. The weight of U.S. trade policy on the loonie could mount "quickly," according to BMO.

Related Articles

Sectors

Sector Update: Financial Stocks Retreat Late Afternoon

Financial stocks were declining in late Tuesday afternoon trading, with the NYSE Financial Index decreasing 0.6% and the State Street Financial Select Sector SPDR ETF (XLF) off by 0.3%.The Philadelphia Housing Index was adding 0.8%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) fell 1.6%.Bitcoin (BTC-USD) was decreasing 0.2% to $75,717, and the yield for 10-year US Treasuries rose 4.2 basis points to 4.29%.In economic news, US retail sales rose 1.7% in March, above the 1.4% increase expected in a Bloomberg-compiled survey and following the previous month's revised 0.7% gain. Removing both motor vehicles and a 15.5% surge in gasoline station sales, retail sales were up 0.6% in March, the same as in February.US pending home sales increased more than expected in March despite higher mortgage rates, data from the National Association of Realtors showed.In corporate news, JPMorgan Chase (JPM) is working to secure approval from securities regulators in China to launch actively managed exchange-traded funds in the country for the first time, Bloomberg reported. JPMorgan shares were down 1.3%.Coinbase (COIN) and Gemini Titan have been sued by New York Attorney General Letitia James for allegedly violating the state laws against illegal gambling with their prediction markets, Reuters reported, citing complaints filed in a state court in Manhattan. Coinbase shares fell past 7%.Washington Trust Bancorp (WASH) reported late Monday a year-over-year decline in Q1 revenue that also trailed analysts' estimates. Its shares tumbled nearly 17%.Barclays (BCS) is facing scrutiny from UK regulators over its use of significant risk transfer, or SRT, transactions, Bloomberg reported. The review, known as a Section 166 probe, has been requested by the Prudential Regulation Authority, the supervisory arm of the Bank of England, the report said. Barclays shares fell 2.9%.

$BCS$COIN$JPM$WASH
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) decreased 1%.In corporate news, Passage Bio (PASG) faces a tougher path after US regulators told the company it will need to run a randomized study to support approval of its experimental treatment PBFT02, a move that adds time, cost, and uncertainty, Wedbush said Tuesday in a report. Wedbush downgraded Passage Bio's stock to neutral from outperform and cut its price target to $8 from $32. Passage Bio shares dropped 2.9%.Merck (MRK) and Japanese health care company Eisai said Tuesday that phase 3 trials of two drug combinations failed to meet primary endpoints of progression-free survival and overall survival as a first-line treatment of patients with advanced clear cell renal cell carcinoma compared with Keytruda plus Lenvima. Merck shares fell 3.7%.UnitedHealth Group (UNH) raised its full-year earnings outlook on Tuesday as the health insurance giant recorded an unexpected annual increase in its first-quarter results. Its shares jumped past 7%.Quest Diagnostics (DGX) shares popped more than 4% after it reported higher Q1 adjusted earnings and net revenue and raised its 2026 outlook.

$DGX$MRK$PASG$UNH
Sectors

Sector Update: Tech Stocks Higher Late Afternoon

Tech stocks advanced late Tuesday afternoon, with the State Street Technology Select Sector SPDR ETF (XLK) increasing 0.7% and the State Street SPDR S&P Semiconductor ETF (XSD) gaining 2.6%.The Philadelphia Semiconductor index rose 1.1%.In corporate news, Amazon.com-backed (AMZN) Anthropic could reach an agreement to deploy its AI models for use by the US Department of Defense, CNBC reported, citing an interview with President Donald Trump. Amazon shares rose 0.6%.Apple (AAPL) said that Tim Cook will step down as chief executive of the iPhone maker and become executive chairman, with hardware engineering veteran John Ternus set to succeed him as CEO. Apple shares were down 2.4%.Moody's (MCO) said Tuesday that it is deepening its partnership with Microsoft (MSFT) by embedding its credit intelligence into Microsoft 365 Copilot and other AI-driven enterprise tools, expanding its presence across financial workflows. Microsoft shares gained 1.5%.Intel (INTC) is expected to report a "slight beat" in its fiscal Q1 results amid robust server CPU demand, RBC Capital Markets said in a note. Intel shares rose 0.2%.

$AAPL$AMZN$INTC$MSFT